These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29407960)

  • 1. An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
    Chollet A; Maveyraud L; Lherbet C; Bernardes-Génisson V
    Eur J Med Chem; 2018 Feb; 146():318-343. PubMed ID: 29407960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the enoyl-ACP reductase of Mycobacterium tuberculosis (InhA) in the apo-form and in complex with the active metabolite of isoniazid pre-formed by a biomimetic approach.
    Chollet A; Mourey L; Lherbet C; Delbot A; Julien S; Baltas M; Bernadou J; Pratviel G; Maveyraud L; Bernardes-Génisson V
    J Struct Biol; 2015 Jun; 190(3):328-37. PubMed ID: 25891098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities.
    Schroeder EK; Basso LA; Santos DS; de Souza ON
    Biophys J; 2005 Aug; 89(2):876-84. PubMed ID: 15908576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
    Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
    Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
    Lu XY; You QD; Chen YD
    Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X; Alian A; Ortiz de Montellano PR
    Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
    Khan AM; Shawon J; Halim MA
    J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
    Rawat R; Whitty A; Tonge PJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis for Inhibition of Enoyl-[Acyl Carrier Protein] Reductase (InhA) from Mycobacterium tuberculosis.
    de Ávila MB; Bitencourt-Ferreira G; de Azevedo WF
    Curr Med Chem; 2020; 27(5):745-759. PubMed ID: 30501592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
    da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
    J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidating isoniazid resistance using molecular modeling.
    Wahab HA; Choong YS; Ibrahim P; Sadikun A; Scior T
    J Chem Inf Model; 2009 Jan; 49(1):97-107. PubMed ID: 19067649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis.
    Quémard A; Sacchettini JC; Dessen A; Vilcheze C; Bittman R; Jacobs WR; Blanchard JS
    Biochemistry; 1995 Jul; 34(26):8235-41. PubMed ID: 7599116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.